A Controlled Study of Solriamfetol for Attention Deficit Hyperactivity Disorder (ADHD) in Adults

PHASE2/PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 6, 2021

Primary Completion Date

January 27, 2023

Study Completion Date

January 27, 2023

Conditions

Attention Deficit Hyperactivity Disorder

Interventions

DRUG

Solriamfetol 75 MG

Daily oral consumption

DRUG

Solriamfetol 150 MG

Daily oral consumption

OTHER

Placebo

Trial Locations (1)

Massachusetts General Hospital, Boston

All Listed Sponsors

lead

Massachusetts General Hospital

OTHER

NCT04839562 - A Controlled Study of Solriamfetol for Attention Deficit Hyperactivity Disorder (ADHD) in Adults | Biotech Hunter | Biotech Hunter